Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-11-13: Form 8-K; Period of report 2017-11-10; Description 8.01 Other Events; Details 8.01.
- 2017-11-07: Form 8-K; Period of report 2017-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-10-17: Form 8-K; Period of report 2017-10-13; Description 8.01 Other Events; Details 8.01.
- 2017-08-03: Form 8-K; Period of report 2017-08-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-11-13 | 8-K | 2017-11-10 | 8.01 Other Events | 8.01 On November 10, 2017, Infinity Pharmaceuticals, Inc. issued a press release announcing data from its Phase 1/1b clinical study of IPI-549, a selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor. | d491319d8k.htm |
| 2017-11-07 | 8-K | 2017-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2017, we issued a press release announcing our results for the quarter ended September 30, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. | d492748d8k.htm |
| 2017-10-17 | 8-K | 2017-10-13 | 8.01 Other Events | 8.01 On October 13, 2017, Infinity Pharmaceuticals, Inc. (“Infinity”) received a $6,000,000 cash payment from Verastem, Inc. (“Verastem”) under the Amended and Restated License Agreement effective October 29, 2016 between Infinity and Verastem. | d478734d8k.htm |
| 2017-08-03 | 8-K | 2017-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2017, we issued a press release announcing our results for the quarter ended June 30, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. | d413441d8k.htm |
| 2017-07-27 | 8-K | 2017-07-26 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On July 26, 2017, Infinity Pharmaceuticals, Inc. (the “Company”, “we”, or “our”) entered into a third amendment (the “Third Amendment”) to our Amended and Restated Development and License Agreement with Intellikine LLC (“Intellikine” and such agreement, as amended, the “Intellikine Agreement”). 2.03 The information provided in Item 1.01 relating to the Note is hereby incorporated by reference into this Item 2.03. 3.02 The information provided in Item 1.01 relating to the Note is hereby incorporated by reference into this Item 3.02. | d420997d8k.htm |
| 2017-06-20 | 8-K | 2017-06-15 | 1.02 Termination of a Material Definitive Agreement; 2.05 Costs Associated with Exit or Disposal Activities | 1.02 On September 25, 2014, Infinity Pharmaceuticals, Inc. (“we”, “us”, or “our”) entered into a lease agreement (the “Base Lease”) with BHX, LLC, as trustee of 784 Realty Trust (the “Landlord”), for the lease of approximately 61,000 square feet of office space at 784 Memorial Drive, Cambridge, Massachusetts. 2.05 The text of Item 1.02 of this Current Report on Form 8-K, which describes the facts and circumstances of the termination of our Base Lease and the related disposal of our building and building improvements, is hereby incorporated by reference into this Item 2.05. | d412152d8k.htm |
| 2017-06-02 | 8-K | 2017-05-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 On May 31, 2017, Infinity Pharmaceuticals, Inc. (“we”, “us”, or “our”) and BHX, LLC, as trustee of 784 Realty Trust (the “Landlord”), entered into a third amendment (the “Third Lease Amendment”) to that certain lease dated September 25, 2014 (as amended, the “Lease”) for the lease of office space at 784 Memorial Drive, Cambridge, MA 02139 (the “Premises”). | d407459d8k.htm |
| 2017-05-26 | 8-K | 2017-05-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | d401194d8k.htm | |
| 2017-05-22 | 8-K | 2017-05-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 On May 18, 2017, Infinity Pharmaceuticals, Inc. (“we”, “us”, or “our”) and BHX, LLC, as trustee of 784 Realty Trust (the “Landlord”), entered into a second amendment (the “Second Lease Amendment”), effective May 1, 2017, to that certain lease dated September 25, 2014 (the “Lease”) for the lease of office space at 784 Memorial Drive, Cambridge, MA 02139 (the “Premises”). | d402227d8k.htm |
| 2017-05-09 | 8-K | 2017-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2017, we issued a press release announcing our results for the quarter ended March 31, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. | d393926d8k.htm |
| 2017-04-06 | 8-K | 2017-04-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On April 5, 2017, José Baselga, M.D., Ph.D., informed our company of his decision to retire from our Board of Directors effective at the end of his current term, which expires on the date of our 2017 Annual Meeting of Stockholders (the “Annual Meeting”). | d371294d8k.htm |
| 2017-03-29 | 8-K | 2017-03-27 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 27, 2017, Infinity Pharmaceuticals, Inc. (“we”, “us”, or “our”) and BHX, LLC, as trustee of 784 Realty Trust (the “Landlord”), entered into an amendment (the “Lease Amendment”) to that certain lease dated September 25, 2014, (the “Lease”) for the lease of office space at 784 Memorial Drive, Cambridge, MA 02139 (the “Premises”), under which we and Landlord agreed to the early termination of the Lease subject to the satisfaction of specified contingencies and payment of a termination payment, as described in more detail below. | d368632d8k.htm |
| 2017-03-14 | 8-K | 2017-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2017, we issued a press release announcing our results for the year ended December 31, 2016 and will conduct a previously announced, publicly available conference call to discuss those results. | d361943d8k.htm |
| 2017-01-09 | 8-K | 2017-01-09 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2016, the Company announced on January 9, 2017, that it expects to report that it had approximately $92.1 million in cash and investments (unaudited) as of December 31, 2016. 8.01 On January 9, 2017, the Company issued a press release announcing its 2017 business goals and financial guidance. | d324715d8k.htm |
| 2017-01-04 | 8-K | 2016-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On December 30, 2016, Julian Adams, Ph.D., informed Infinity Pharmaceuticals, Inc. (the “Company”) of his decision to retire effective January 6, 2017. | d317502d8k.htm |